Resources Repository
-
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Technology Assessment | Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Europe -
BookPublication 2012Elgar Companion to Health Economics, 2nd Edition
This collection brings together more than 50 contributions from some of the most influential researchers in …
This collection brings together more than 50 contributions from some of the most influential researchers in health economics. It covers theoretical and empirical issues in health economics, with a range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated. The Elgar Companion to Health Economics, Second Edition…
Cost-Effectiveness Analysis | Value of Information | Decision Theory | Probability/Bayes | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
BookPublication 2010Problem Solving, Decision Making, and Professional Judgment
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment …
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment and decision making literature, and behavioral economics. It combines quantitative approaches to empirical analysis and decision making (i.e., statistics and decision science) with the psychological literature illustrating the systematic errors of the intuitive decision maker.
Cost-Effectiveness Analysis | Value of Information | Probability/Bayes | Preferences/Values | Priority Setting/Ethics | Test Performance | Decision Analysis | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
BookPublication 2007Advances in Decision Analysis: From Foundations to Applications
Decision analysis consists of a prescriptive theory and associated models and tools that aid individuals …
Decision analysis consists of a prescriptive theory and associated models and tools that aid individuals or groups confronted with complex decision problems in a wide variety of contexts. Decision analysis can be applied to the environment, health and medicine, engineering, public policy, and business. This book reviews and extends the material typically presented in introductory texts on decision analysis. It covers the broad scope of decision analysis at an advanced level and includes chapters written by…
Cost-Effectiveness Analysis | Value of Information | Decision Theory | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Mathematical Models | Decision Analysis | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Cost-Effectiveness Analysis | Value of Information | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Evidence Synthesis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Cost-Effectiveness Analysis | Value of Information | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | State-Transition | Decision Analysis | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global | North America | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Extended Cost-Effectiveness Analysis
Health policies are intended to increase the uptake of effective and efficient interventions and result …
Health policies are intended to increase the uptake of effective and efficient interventions and result in health gains (e.g., premature mortality and morbidity averted). Health policies can also provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, social and health insurance programs can prevent illness-related impoverishment and provide financial risk protection. Health policies can also improve the distribution of health in the population and promote health…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Social Determinants | Health Systems | Policy/Regulation | Culture/Society | Economics/Finance | Health/Medicine | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine